

# GRI Content Index

## General disclosures

### GRI 2: General Disclosures 2021

GRI Standard and Disclosure		Reference
2-1	Organizational details	<a href="#">Fundamental information about the Group</a> <a href="#">List of shareholdings</a>
2-2	Entities included in the organization's sustainability reporting	<a href="#">List of shareholdings</a> <a href="#">ESRS 2 BP-1</a>
2-3	Reporting period, frequency and contact point	<a href="#">Assurance report</a>
2-4	Restatements of information	<a href="#">ESRS 2 BP-2</a>
2-5	External assurance	<a href="#">Assurance report</a>
2-6	Activities, value chain and other business relationships	<a href="#">Fundamental information about the Group</a> <a href="#">Macro-economic and sector-specific environment</a> <a href="#">ESRS 2 SBM-1</a>
2-7	Employees	<a href="#">ESRS 2 SBM-1</a> <a href="#">S1-6</a>
2-9	Governance structure and composition	<a href="#">Management</a> <a href="#">Statement on corporate governance</a> <a href="#">Procedures of the Boards</a> <a href="#">Objectives of the Supervisory Board</a> <a href="#">ESRS 2 GOV-1</a>
2-10	Nomination and selection of the highest governance body	<a href="#">Procedures of the Boards</a> <a href="#">Objectives of the Supervisory Board</a> <a href="#">Promote women in management positions</a> <a href="#">Diversity policy</a>
2-11	Chair of the highest governance body	<a href="#">Statement on corporate governance</a>
2-12	Role of the highest governance body in overseeing the management of impacts	<a href="#">Report of the Supervisory Board</a> <a href="#">Report on Risks and Opportunities</a> <a href="#">ESRS 2 GOV-1</a> <a href="#">ESRS 2 SBM-2</a>
2-13	Delegation of responsibility for managing impacts	<a href="#">ESRS 2 GOV-1</a>
2-14	Role of the highest governance body in sustainability reporting	<a href="#">ESRS 2 GOV-2</a> <a href="#">ESRS 2 IRO-1</a>
2-15	Conflicts of interest	<a href="#">Information on corporate governance practices</a>
2-17	Collective knowledge of the highest governance body	<a href="#">Information on corporate governance practices</a> <a href="#">ESRS 2 GOV-1</a>
2-18	Evaluation of the performance of the highest governance body	<a href="#">Procedures of the Boards</a> <a href="#">Articles of association</a> <a href="#">Compensation report</a>
2-19	Remuneration policies	<a href="#">Compensation report</a> <a href="#">ESRS 2 GOV-3</a>
2-20	Process to determine remuneration	<a href="#">Compensation report</a> <a href="#">Voting results Annual General Meeting 2025</a> <a href="#">ESRS 2 GOV-3</a>
2-22	Statement on sustainable development strategy	<a href="#">ESRS 2 SBM-1</a>
2-23	Policy commitments	<a href="#">ESRS 2 GOV-4</a> <a href="#">S1-1</a> <a href="#">S2-1</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">G1-1 (Corporate culture)</a> <a href="#">G1-1 (Animal welfare)</a>

<b>GRI Standard and Disclosure</b>		<b>Reference</b>
2-24	Embedding policy commitments	<a href="#">Information on corporate governance practices</a> <a href="#">ESRS 2 GOV-2</a> <a href="#">S2-4</a> <a href="#">G1-1 (Corporate culture)</a> <a href="#">G1-1 (Anti-corruption and bribery)</a> <a href="#">G1-1 (Animal welfare)</a>
2-25	Processes to remediate negative impacts	<a href="#">Report on Risks and Opportunities</a> <a href="#">S1-1</a> <a href="#">S1-3</a> <a href="#">S2-1</a> <a href="#">S2-3</a> <a href="#">S2-4</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-3 (Health and safety of our patients)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a>
2-26	Mechanisms for seeking advice and raising concerns	<a href="#">G1-1 (Corporate culture)</a> <a href="#">G1-1 (Anti-corruption and bribery)</a> <a href="#">G1-1 (Animal welfare)</a>
2-27	Compliance with laws and regulations	<a href="#">Other provisions</a> <a href="#">S1-17</a> <a href="#">S4-3 (Health and safety of our patients)</a>
2-28	Membership associations	<a href="#">S2-4</a> <a href="#">G1 MDR-A (Animal welfare)</a>
2-29	Approach to stakeholder engagement	<a href="#">ESRS 2 SBM-2</a> <a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a>
2-30	Collective bargaining agreements	<a href="#">S1-8</a>

### **GRI 3: Material Topics 2021**

<b>GRI Standard and Disclosure</b>		<b>Reference</b>
3-1	Process to determine material topics	<a href="#">ESRS 2 IRO-1</a>
3-2	List of material topics	<a href="#">ESRS 2 SBM-3</a>

## Economic standards

### GRI 201: Economic Performance 2016

GRI Standard and Disclosure	Reference
201: 3-3 Management of material topics	<a href="#">Statement on Corporate Governance</a> <a href="#">Economic performance</a> <a href="#">Pension schemes</a> <a href="#">Report on Risks and Opportunities</a> <a href="#">ESRS 2 SBM-1</a> <a href="#">ESRS 2 SBM-3</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
201-1 Direct economic value generated and distributed	<a href="#">Consolidated Income Statement</a> <a href="#">Consolidated Cash Flow Statement</a> <a href="#">Operating Activities</a> <a href="#">Personnel expenses</a> <a href="#">ESRS 2 SBM-1</a>
201-2 Financial implications and other risks and opportunities due to climate change	<a href="#">CDP Climate change</a> <a href="#">CDP Water Security</a> <a href="#">Report on Risks and Opportunities</a> <a href="#">ESRS 2 SBM-3</a> <a href="#">E1-3</a>
201-3 Defined benefit plan obligations and other retirement plans	<a href="#">Pension schemes</a>
201-4 Financial assistance received from government	<a href="#">Property, plant and equipment</a> <a href="#">Research and development costs</a>

### GRI 203: Indirect Economic Impacts 2016

GRI Standard and Disclosure	Reference
203: 3-3 Management of material topics	<a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
203-2 Significant indirect economic impacts	<a href="#">S2-4</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a>

### GRI 205: Anti-corruption 2016

GRI Standard and Disclosure	Reference
205: 3-3 Management of material topics	<a href="#">Anti-corruption and anti-bribery</a>
205-1 Operations assessed for risks related to corruption	<a href="#">G1-3</a>
205-2 Communication and training about anti-corruption policies and procedures	<a href="#">G1-3</a>
205-3 Confirmed incidents of corruption and actions taken	<a href="#">G1-4</a>

### GRI 206: Anti-competitive Behavior 2016

GRI Standard and Disclosure	Reference
206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	<a href="#">Report on Risks and Opportunities</a>

## Environmental standards

### GRI 301: Materials 2016

GRI Standard and Disclosure	Reference
301: 3-3 Management of material topics	<a href="#">E5-1</a> <a href="#">E5-2</a> <a href="#">E5-3</a>
301-1 Materials used by weight or volume	<a href="#">E5-4</a>
301-2 Recycled input materials used	<a href="#">E5-4</a>
301-3 Reclaimed products and their packaging materials	<a href="#">E5-1</a> <a href="#">E5-2</a> <a href="#">E5-3</a> <a href="#">E5-4</a> <a href="#">E5-5</a>

### GRI 302: Energy 2016

GRI Standard and Disclosure	Reference
302: 3-3 Management of material topics	<a href="#">E1-2</a> <a href="#">E1-3</a> <a href="#">E1-4</a>
302-1 Energy consumption within the organization	<a href="#">E1-5</a>
302-3 Energy intensity	<a href="#">E1-5</a>
302-4 Reduction of energy consumption	<a href="#">E1-2</a> <a href="#">E1-3</a> <a href="#">E1-4</a> <a href="#">E1-5</a>
302-5 Reductions in energy requirements of products and services	<a href="#">E1-2</a> <a href="#">E1-3</a> <a href="#">E1-4</a> <a href="#">E1-5</a>

### GRI 303: Water and Effluents 2018

GRI Standard and Disclosure	Reference
Management of material topics	<a href="#">E2-1 (Pollution of water)</a> <a href="#">E2-2 (Pollution of water)</a> <a href="#">E2-3 (Pollution of water)</a> <a href="#">E3-1</a> <a href="#">E3-2</a> <a href="#">E3-3</a>
Interactions with water as a shared resource	<a href="#">ESRS 2 IRO-1</a> <a href="#">E3-2</a> <a href="#">E3-3</a>
Water withdrawal	<a href="#">E3 MDR-M</a>

**GRI 305: Emissions 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
305: 3-3 Management of material topics	<a href="#">E1-2</a> <a href="#">E1-3</a> <a href="#">E1-4</a> <a href="#">E1-7</a> <a href="#">E2-1 (Pollution of water)</a> <a href="#">E2-1 (Pollution of soil)</a> <a href="#">E2-1 (Substances of concern and substances of very high concern)</a> <a href="#">E2-2 (Pollution of water)</a> <a href="#">E2-2 (Pollution of soil)</a> <a href="#">E2-2 (Substances of concern and substances of very high concern)</a> <a href="#">E2-3 (Pollution of water)</a> <a href="#">E2-3 (Pollution of soil)</a> <a href="#">E2-3 (Substances of concern and substances of very high concern)</a>
305-1 Direct (Scope 1) GHG emissions	<a href="#">E1-4</a> <a href="#">E1-6</a>
305-2 Energy indirect (Scope 2) GHG emissions	<a href="#">E1-4</a> <a href="#">E1-6</a>
305-3 Other indirect (Scope 3) GHG emissions	<a href="#">CDP Climate change</a> <a href="#">E1-4</a> <a href="#">E1-6</a>
305-4 GHG emissions intensity	<a href="#">E1-6</a>
305-5 Reduction of GHG emissions	<a href="#">CDP Climate change</a> <a href="#">E1-7</a>
305-6 Emissions of ozone-depleting substances (ODS)	<a href="#">E2-5 (Substances of concern and substances of very high concern)</a>
305-7 Nitrogen oxides (NO <sub>x</sub> ), sulfur oxides (SO <sub>x</sub> ), and other significant air emissions	<a href="#">E2-4 (Pollution of water)</a>

**GRI 306: Waste 2020**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
306: 3-3 Management of material topics	<a href="#">E5-1</a> <a href="#">E5-2</a> <a href="#">E5-3</a>
306-1 Waste generation and significant waste-related impacts	<a href="#">E5 SBM-3</a> <a href="#">E5-4</a>
306-2 Management of significant waste-related impacts	<a href="#">E5-2</a> <a href="#">E5-5</a>
306-3 Waste generated	<a href="#">E5-5</a>
306-4 Waste diverted from disposal	<a href="#">E5-5</a>
306-5 Waste directed to disposal	<a href="#">E5-5</a>

**GRI 306: Effluents and Waste 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
306-3 Significant spills	<a href="#">E2-1 (Pollution of water)</a> <a href="#">E2-1 (Pollution of soil)</a> <a href="#">E2-1 (Substances of concern and substances of very high concern)</a> <a href="#">E2-2 (Pollution of water)</a> <a href="#">E2-2 (Pollution of soil)</a> <a href="#">E2-2 (Substances of concern and substances of very high concern)</a> <a href="#">E2-3 (Pollution of water)</a> <a href="#">E2-3 (Pollution of soil)</a> <a href="#">E2-3 (Substances of concern and substances of very high concern)</a> <a href="#">E2-4 (Pollution of water)</a> <a href="#">E2-5 (Substances of concern and substances of very high concern)</a>

## Social standards

### GRI 401: Employment 2016

GRI Standard and Disclosure	Reference
401: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-5</a>
401-1 New employee hires and employee turnover	<a href="#">S1-6</a>
401-3 Parental leave	<a href="#">S1-15</a>

### GRI 402: Labor/Management Relations 2016

GRI Standard and Disclosure	Reference
402: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>

### GRI 403: Occupational Health and Safety 2018

GRI Standard and Disclosure	Reference
403: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
403-1 Occupational health and safety management system	<a href="#">S1-1</a>
403-2 Hazard identification, risk assessment, and incident investigation	<a href="#">S1-3</a>
403-4 Worker participation, consultation, and communication on occupational health and safety	<a href="#">S1-1</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-MDR-M</a>
403-5 Worker training on occupational health and safety	<a href="#">S1-1</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-MDR-M</a>
403-6 Promotion of worker health	<a href="#">S1-1</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-MDR-M</a>
403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	<a href="#">S2-4</a>
403-8 Workers covered by an occupational health and safety management system	<a href="#">S1-14</a>
403-9 Work-related injuries	<a href="#">S1-4</a> <a href="#">S1-14</a>
403-10 Work-related ill health	<a href="#">S1-4</a> <a href="#">S1-14</a>

**GRI 404: Training and Education 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
404: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
404-2 Programs for upgrading employee skills and transition assistance programs	<a href="#">S1-1</a>
404-3 Percentage of employees receiving regular performance and career development reviews	<a href="#">S1-13</a>

**GRI 405: Diversity and Equal Opportunity 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
405: 3-3 Management of material topics	<a href="#">Objectives of the Supervisory Board</a> <a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
405-1 Diversity of governance bodies and employees	<a href="#">Executive Board</a> <a href="#">Supervisory Board</a> <a href="#">Objectives of the Supervisory Board</a> <a href="#">Diversity policy</a> <a href="#">GOV-1</a> <a href="#">S1-9</a>
405-2 Ratio of basic salary and remuneration of women to men	<a href="#">S1-16</a>

**GRI 406: Non-discrimination 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
406: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> <a href="#">S1-4</a> <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a> <a href="#">S4 SBM-3</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
406-1 Incidents of discrimination and corrective actions taken	<a href="#">S1-17</a>

**GRI 407: Freedom of Association and Collective Bargaining 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
407: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> S1-4 <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	<a href="#">S1-1</a> S1-4 <a href="#">S1-5</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>

**GRI 408: Child Labor 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
408: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> S1-4 <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
408-1 Operations and suppliers at significant risk for incidents of child labor	<a href="#">S1 SBM-3</a> <a href="#">S1-1</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a>

**GRI 409: Forced or Compulsory Labor 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
409: 3-3 Management of material topics	<a href="#">S1-1</a> <a href="#">S1-2</a> S1-4 <a href="#">S1-5</a> <a href="#">S1-17</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a> <a href="#">S2-2</a> <a href="#">S2-4</a> <a href="#">S2-5</a>
409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	<a href="#">S1 SBM-3</a> <a href="#">S1-1</a> <a href="#">S2 SBM-3</a> <a href="#">S2-1</a>

**GRI 416: Customer Health and Safety 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
416: 3-3 Management of material topics	<a href="#">Report on Risks and Opportunities</a> <a href="#">S4 SBM-3 (Health and safety of our patients)</a> <a href="#">S4 SBM-3 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Health and safety of our patients)</a>
416-1 Assessment of the health and safety impacts of product and service categories	<a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	<a href="#">Report on Risks and Opportunities</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a>

**GRI 417: Marketing and Labeling 2016**

<b>GRI Standard and Disclosure</b>	<b>Reference</b>
417: 3-3 Management of material topics	<a href="#">S4 SBM-3 (Health and safety of our patients)</a> <a href="#">S4 SBM-3 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
417-1 Requirements for product and service information and labeling	<a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>
417-2 Incidents of non-compliance concerning product and service information and labeling	<a href="#">Report on Risks and Opportunities</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a>
417-3 Incidents of non-compliance concerning marketing communications	<a href="#">Report on Risks and Opportunities</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a>

**GRI 418: Customer Privacy 2016**

GRI Standard and Disclosure	Reference
418: 3-3 Management of material topics	<a href="#">S4 SBM-3 (Health and safety of our patients)</a> <a href="#">S4 SBM-3 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Health and safety of our patients)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>

## Additional material topics

### Clinical studies

GRI Standard and Disclosure		Reference
3-3	Management of material topics	<a href="#">S4 SBM-3 (Health and safety of our patients)</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-5 (Health and safety of our patients)</a>

### Animal welfare

GRI Standard and Disclosure		Reference
3-3	Management of material topics	<a href="#">G1-1 (Animal welfare)</a> <a href="#">G1 MDR-A (Animal welfare)</a> G1 MDR-T (Animal welfare) <a href="#">G1 MDR-M (Animal welfare)</a>

### Access to health

GRI Standard and Disclosure		Reference
3-3	Management of material topics	<a href="#">S4 SBM-3 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>

### Prices of medicines

GRI Standard and Disclosure		Reference
3-3	Management of material topics	<a href="#">S4 SBM-3 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-1 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-2 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-4 (Access to our products and services and access to (quality) information)</a> <a href="#">S4-5 (Access to our products and services and access to (quality) information)</a>

### Product-related crime

GRI Standard and Disclosure		Reference
3-3	Management of material topics	<a href="#">S4 SBM-3 (Health and safety of our patients)</a> <a href="#">S4-1 (Health and safety of our patients)</a> <a href="#">S4-2 (Health and safety of our patients)</a> <a href="#">S4-4 (Health and safety of our patients)</a> <a href="#">S4-5 (Health and safety of our patients)</a>

### Bioethics

GRI standard and disclosure		Reference
3-3	Management of material topics	<a href="#">Bioethics SBM-3</a> <a href="#">Bioethics MDR-P</a> <a href="#">Bioethics MDR-A</a> <a href="#">Bioethics MDR-T</a>

### Digital ethics

GRI standard and disclosure		Reference
3-3	Management of material topics	<a href="#">Digital ethics SBM-3</a> <a href="#">Digital ethics MDR-P</a> <a href="#">Digital ethics MDR-A</a> <a href="#">Digital ethics MDR-T</a>